Form D · Biotechnology
Generation Bio Co.
Cambridge, MA · CIK 0001733294
Offering snapshot reported Jan 14, 2020 · SEC filing
- Reported sold
- $111M Offering amount: $111M
- Investors reported
- 54 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 9, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 14, 2020 | Initial | $111,471,806 | No comparison | 54 | SEC filing |
| Mar 5, 2018 | Initial | $100,370,802 | No comparison | 26 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-357901
Source: Form D, filed Jan 14, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mark Angelino | Executive |
| Gustav Christensen | Director |
| Glenn Goddard | Executive |
| Thomas Graney | Executive |
| Jeff Jonas | Director |
| Geoffrey Mc Donough | Director, Executive |
| Geoff Mc Donoughy | Director, Executive |
| Donald Nicholson | Director |
| Anthony Quinn | Director |
| Jason Rhodes | Director |
| Charlie Rowland | Director |
| Catherine Stehman Breen | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
301 Binney Street
Cambridge, MA, 02142
Cambridge, MA, 02142